Processa Pharmaceuticals (PCSA)
Develops altered-metabolism cancer therapies from in-licensed cytotoxic drugs.
Something off on this page? Send us feedback.
Develops in-licensed cancer-drug candidates that aim to improve the efficacy-safety profile of established cytotoxic therapies, then seeks to license programs to partners near pivotal studies. The portfolio centers on the clinical NGC-Cap program and preclinical NGC-Iri.
Develops next-generation cancer therapies that alter the metabolism or tissue distribution of established cytotoxic drugs. The lead program, NGC-Cap, pairs PCS6422 with capecitabine to modify drug metabolism and exposure in advanced or metastatic breast cancer. NGC-Iri is a preclinical analog of irinotecan's active metabolite designed to shift drug distribution toward cancer cells and away from normal tissue.
Operates through an in-license-develop-partner model, using a Regulatory Science Approach that incorporates dose-response principles associated with FDA Project Optimus. The intent is to advance assets toward pivotal-study milestones, then license them to partners; there are no approved products or product revenue. All current assets are in-licensed, and the lead program's Elion license remains under active litigation.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
No analyst notes in the last 24 months.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $196.3K · Total debt $0 · Total assets $2.1M · Shareholders' equity −$317.3K
- Revenue
- $0
- Operating income
- −$2.3M
- Net income
- −$3.3M
No dividends on record.
| Insiders10 holders · as of Aug 11, 2026 | 3.76% | 105.0K shares | |
| Strategic holders1 holder · as of Feb 23, 2026 | 10.94% | 305.6K shares | |
| Otherremainder | 85.30% | 2.38M shares |
2.79M company shares as of Sep 3, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
HX Entertainment LtdStrategic | 10.94% | 305,644 | 13Dfiled Feb 23, 2026 ↗ |
Soleus Capital Master Fund, L.P.Institution | 5.76% | 160,943 | 13Gfiled Aug 18, 2026 ↗ |
George K. NgInsiderdirector, officer: Chief Executive Officer | 0.83% | 23,112 | Form 4filed Aug 11, 2026 ↗ |
David YoungInsiderdirector, officer: Pres. Research & Development | 0.78% | 21,729 | Form 4filed Jul 1, 2026 ↗ |
Russell SkibstedInsiderofficer: Chief Financial Officer | 0.60% | 16,689 | Form 4filed Jul 1, 2026 ↗ |
| See all 23 → | |||
13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 30, 2026 | David Young | director, officer: Pres. Research & Development | +2,531 | $1.93 |
| Jun 30, 2026 | Russell Skibsted | officer: Chief Financial Officer | +3,277 | $1.93 |
| Jul 1, 2026 | George K. Ng | director, officer: Chief Executive Officer | +3,057 | $1.93 |
| Jun 30, 2026 | Patrick Lin | officer: Chief Business - Strategy Off | +2,106 | $1.93 |
| Jun 30, 2026 | Wendy Guy | officer: Chief Administrative Officer | +2,436 | $1.93 |
- Pfizer
Camptosar sets the conventional irinotecan benchmark in solid tumors.
- ANI Pharmaceuticals
Reglan is the only approved drug benchmark for gastroparesis therapy.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Processa Pharmaceuticals | $2.09 | +1.95% | $5.8M | — | — | — | — |
| Pfizer | $28.99 | −0.15% | $165.40B | 38.3 | 10.4 | 2.6 | +2.6% |
| ANI Pharmaceuticals | $73.07 | +1.60% | $1.66B | 15.8 | 7.8 | 1.7 | +25.9% |
| Median | 27.1 | 9.1 | 2.1 | +14.2% |